Capital raised by Linnaeus Therapeutics
5 Form D filings · first filed Aug 2025 · Haddonfield, NJ
Attorney-in-fact
Signatory on Linnaeus Therapeutics's Form D filings · $6.3M raised across 5
Anthony Gruzdis is on file as Attorney-in-fact at Linnaeus Therapeutics in Haddonfield, NJ. Linnaeus Therapeutics has 5 Form D filings on record, $6.3M raised in total. Anthony Gruzdis appears as a signatory on the company's filings.
LNS8801 is an orally administered, small-molecule agonist of the G protein-coupled estrogen receptor (GPER). It is being developed for cancer treatment and functions by rapidly depleting c-Myc protein levels, leading to antitumor activity and demonstrating target engagement in clinical trials.
